Drugs / JS019
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05374226 | Mar 2022 → Dec 2023 | neoplasm | Suzhou Kebo Ruijun Biotechnology Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT05508373 | Mar 2022 → Jun 2024 | cancer | Suzhou Kebo Ruijun Biotechnology Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05508373 ↗ |
| Modality | Monoclonal antibody | “Recombinant Fully Human Anti-CD39 Monoclonal Antibody JS019” NCT05374226 ↗ |
| Route | Intravenous | “The subjects are treated with JS019 by intravenous infusion” NCT05374226 ↗ |